TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))	Docket No. RLL-256.2CIPUS

In Re Application Of: **SALMAN et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/552,503		Unknown	26,815	Unknown	2262

Title: **AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS**

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

   ☐ the statement specified in 37 CFR 1.97(e);

   OR

   ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))	Docket No. RLL-256.2CIPUS

In Re Application of: **SALMAN et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/552,503		Unknown	26,815	Unknown	2262

Title: **AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

☐ A check in the amount of is attached.

☒ The Director is hereby authorized to charge and credit Deposit Account No. **50-0912** as described below.

- ☐ Charge the amount of
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by ~~First Class~~ EXPRESS Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as ~~first class~~ EXPRESS mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR ~~1.8(a)~~ 1.10] on

June 8, 2006
(Date)

Signature of Person Mailing Correspondence

Michelle Morgan

Typed or Printed Name of Person Mailing Certificate

***This certificate may only be used if paying by deposit account.**

Signature

Dated: **June 8, 2006**

George E. Heibel, Esq.
Reg. No. 42,648

CUSTOMER NO. 26,815

cc:

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-256.2CIPUS	Serial No.: 10/552,503
	Applicants: SALMAN *et al.*	
	Filed: 10/7/2005	Group:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/G.S./	A1	2,490,714	12/6/1949	Searle	260	239	
	A2	3,176,019	3/30/1965	Campbell *et al.*	260	293.4	
	A3	5,001,160	3/19/1991	McPherson *et al.*	514	255	
	A4	5,164,402	11/17/1992	Brighty	514	300	
	A5	5,281,601	1/25/1994	Cross *et al.*	514	320	
	A6	5,397,800	3/14/1995	Alker *et al.*	514	413	
	A7	5,948,792	9/7/1999	Tsuchiya *et al.*	514	317	
	A8	6,130,232	10/10/2000	Mase *et al.*	514	318	
	A9	6,174,900	1/16/2001	Okada *et al.*	514	317	
	A10	6,313,312	11/6/2001	Banks *et al.*	548	452	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES | NO
/G.S./	B1	CA 2155320	8/19/1993	Canada	C07D	211/68	|
	B2	EP 0 325 571	7/26/1989	EPO	C07C	215/54	|
	B3	EP 0 388 054	9/19/1990	EPO	C07D	207/08	|
	B4	EP 0 413 455	2/20/1991	EPO	C07D	401/04	|
	B5	EP 0 613 232	8/31/1994	EPO	H02M	3/335	|
	B6	EP 0 801 067	10/15/1997	EPO	C07D	453/02	|
	B7	EP 0 823 423	2/11/1998	EPO	C07D	211/46	|
	B8	EP 0 863 141	9/9/1998	EPO	C07D	401/06	|
	B9	GB 940,540	10/30/1963	UK	C07C		|
	B10	JP 135958/1994	5/17/1994	Japan	C07D	333/16	|
	B11	JP 92921/1994	4/5/1994	Japan	C07C	237/20	|

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-256.2CIPUS	Serial No.: 10/552,503
	Applicants: SALMAN *et al.*	
	Filed: 10/7/2005	Group:

/G.S./	B12	WO 91/09013	6/27/1991	PCT	C07D	207/08	
	B13	WO 93/16018	8/19/1993	PCT	C05F	17/02	
	B14	WO 93/16048	8/19/1993	PCT	C07D	211/26	
	B15	WO 96/33973	10/31/1996	PCT	C07D	211/46	
	B16	WO 97/45414	12/4/1997	PCT	C07D	211/58	
	B17	WO 98/05641	2/12/1998	PCT	C07D	211/46	
	B18	WO 98/29402	7/9/1998	PCT	C07D	311/20	
	B19	WO 98/53814	12/3/1998	PCT	A61K	31/395	
	B20	WO 01/42212	6/14/2001	PCT	C07D	211/48	
	B21	WO 01/42213	6/14/2001	PCT	C07D	211/58	
	B22	WO 01/90081	11/29/2001	PCT	C07D	241/08	
	B23	WO 02/00652	1/3/2002	PCT	C07D	453/02	
	B24	WO 02/04402	1/17/2002	PCT	C07C	219/10	
	B25	WO 02/51841	7/4/2002	PCT	C07D	453/02	
	B26	WO 02/06241	1/24/2002	PCT	C07D	223/16	
	B27	WO 02/53564	7/11/2002	PCT	C07D	453/02	
	B28	WO 04/004629	1/15/2004	PCT	A61K		
	B29	WO 04/005252	1/15/2004	PCT	C07D	209/52	
	B30	WO 04/014363	2/19/2004	PCT	A61K	31/40	
	B31	WO 04/014853	2/19/2004	PCT	C07D	209/02	
	B32	WO 04/018422	3/4/2004	PCT	C07D	209/52	
	B33	WO 04/052857	6/24/2004	PCT	C07D	209/52	
	B34	WO 04/056767	7/8/2004	PCT	C07D	207/14	
	B35	WO 04/056810	7/8/2004	PCT	C07D	405/12	
	B36	WO 04/056811	7/8/2004	PCT	C07D	405/12	
	B37	WO 04/089900	10/21/2004	PCT	C07D	209/52	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-256.2CIPUS	Serial No.: 10/552,503
	Applicants: SALMAN *et al.*	
	Filed: 10/7/2005	Group:

		OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)
/G.S./	C1	de Groat and Yoshimura, "Pharmacology of the Lower Urinary Tract", *Annual Review of Pharmacology and Toxicology*, 41:691-721 (2001)
	C2	Cheng and Prusoff, "Relationship between the inhibition constant (K_I) and the concentration of inhibitor which causes 50 per cent inhibition (I_{50}) of an enzymatic reaction", *Biochemical Pharmacology*, 22:3099-3108 (1973)
	C3	Birdsall et al., "Muscarinic receptors: it's a knockout", *Trends in Pharmacological Sciences*, 22(5):215-219 (2001)
	C4	Brighty et al., "Synthesis of (1α,5α,6α)-6-Amino-3-azabicyclo[3.1.0]hexane, a Novel Achiral Diamine", *Synlett*, 1097-1099 (1996)
	C5	Braish et al., "Construction of the (1α,5α,6α)-6-Amino-3-azabicyclo[3.1.0]hexane Ring System", *Synlett*, 1100-1102 (1996)
	C6	Chapple, "Muscarinic receptor antagonists in the treatment of overactive bladder", *Urology*, 55(Suppl. 5A):33-46 (2000)
	C7	Eglen et al., "Muscarinic receptor ligands and their theraputic potential", *Current Opinion in Chemical Biology*, 3:426-432 (1999)
	C8	Eglen et al., "Theraputic opportunities from muscarinic receptor research", *Trends in Pharmacological Sciences*, 22(8):409-414 (2001)
	C9	Felder et al., "Theraputic Opportunities for Muscarinic Receptors in the Central Nervous System", *Journal of Medicinal Chemistry*, 43(23):4333-4353 (2000)
	C10	Grover et al., "Chiral Mandelic Acid Template Provides a Highly Practical Solution for (S)-Oxybutynin Synthesis", *Journal of Organic Chemistry*, 65:6283-6287 (2000)
	C11	Shacklett and Smith, "The Preparation of Substituted Benzilic Acids", *Journal of the American Chemical Society*, 75:2654-2657 (1953)
	C12	Sagara et al., "Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M_3 Antagonist Discriminating against the Other Receptor Subtypes", *Journal of Medicinal Chemistry*, 45:984-987 (2002)
	C13	Nkpa and Chedekel, "Mechanistic Studies on the Addition of Cysteine to 3,4-Dihydroxyphenylalanine", *Journal of Organic Chemistry*, 46:213-215 (1981)
	C14	Kadin and Cannon, "Esters of *N*-Methyl-3-hydroxypiperidine Having Psychotomimetic Activity. II", *Journal of Organic Chemistry*, 27:240-245 (1962)
	C15	Broadley and Kelly, "Muscarinic Receptor Agonists and Antagonists", *Molecules*, 6:142-193 (2001)
	C16	Moriya et al., "Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland", *Life Sciences*, 64(25):2351-2358 (1999)
	C17	Kubo et al., "Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor", *Nature*, 323(2):411-416 (1986)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-256.2CIPUS	Serial No.: 10/552,503
	Applicants: SALMAN *et al.*	
	Filed: 10/7/2005	Group:

/G.S./	C18	Bonner et al., "Identification of a Family of Muscarinic Acetylcholine Receptor Genes", *Science,* 237:527-531 (1987)
	C19	Steers, "The future direction of neuro-urology drug research", *Current Opinion in CPNS Investigational Drugs,* 2(3):268-282
	C20	Steers, Barrot, Wein, "Voiding dysfunction: diagnosis classification and management", In: *Adult and Pediatric Urology,* ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996)
	C21	Weinstock et al., "A General, One-Step Synthesis of α-keto Esters", *Synthetic Communications,* 11(12):943-946 (1981)
	C22	Vogel's textbook, "Practical Organic Chemistry" 1046-1047 (5th Ed.)
	C23	"Design of prodrugs", ed. H. Bundgaard, Elsevier (1985)

EXAMINER /Golam Shameem/	DATE CONSIDERED 02/02/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.S./